Here we report results from the PATHWAY trial (NCCH1607), which has investigated the benefit of adding palbociclib to tamoxifen in patients with HR+/HER2− advanced breast cancer, in both pre-, peri-, and postmenopausal patients versus tamoxifen alone. Here, HR is linked to breast carcinoma.